Cantargia advance development of antibody CAN04 by a new clinical trial in triple negative breast cancer
Cantargia AB today announced signing a Letter of Intent with the Spanish Breast Cancer Group (GEICAM) to perform a new clinical trial investigating the antibody nadunolimab (CAN04) in combination with carboplatin/gemcitabine for the treatment of patients with advanced triple negative breast cancer (TNBC). The trial will investigate the safety and efficacy of the combination in this difficult to treat breast cancer. The total number of patients is estimated to be up to 120 and includes a randomized part after initial safety lead in. The protocol is planned to be submitted during Q2 2021.